A Phase I, Open-Label, Multiple Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of ARRY-334543 Given on a Daily Oral Regimen in Patients With Advanced Cancer.

Trial Profile

A Phase I, Open-Label, Multiple Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of ARRY-334543 Given on a Daily Oral Regimen in Patients With Advanced Cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Sep 2012

At a glance

  • Drugs Varlitinib (Primary)
  • Indications Advanced breast cancer; Leukaemia; Lymphoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Array BioPharma
  • Most Recent Events

    • 11 Apr 2011 Status changed from active, no longer recruiting to completed.
    • 09 Jun 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 27 Jan 2009 New source identified and integrated (Vanderbilt-Ingram Cancer Center).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top